Phase I study of APG-1387 in Hepatitis B patients.

Trial Profile

Phase I study of APG-1387 in Hepatitis B patients.

Phase of Trial: Phase I

Latest Information Update: 26 Feb 2018

At a glance

  • Drugs APG 1387 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Feb 2018 New trial record
    • 13 Feb 2018 According to the Ascentage Pharma media release, China Food and Drug Administration (CFDA) has accepted the Investigational New Drug (IND) application for APG-1387 for the treatment of the Hepatitis B virus (HBV) infection.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top